Agustín Ruiz Laza
Director of the Biology Core
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Year:
2026
Blood biomarkers have emerged as accurate tools for detecting Alzheimer’s disease (AD) pathology, offering a minimally invasive alternative to traditional diagnostic methods such as imaging and cerebrospinal fluid (CSF) analysis. Yet, the logistics surrounding venipuncture for blood collection, although considerably simpler than the acquisition of imaging and CSF, require precise processing and storage specific to AD biomarkers that are still guided by medical personnel. Consequently, limitations in their widescale use in research and broader clinical implementation exist. The DROP-AD project investigates the potential of dried plasma spot (DPS) and dried blood spot (DBS) analysis, derived from capillary blood, for detecting AD biomarkers, including phosphorylated tau at amino acid 217 (p-tau217), glial fibrillary acidic protein and neurofilament light. Here, 337 participants from 7 centers were included, with 304 participants providing paired capillary DPS or DBS and venous plasma samples. We observed strong correlations between DPS p-tau217 and venous plasma p-tau217 ( r S = 0.74, P < 0.001). DPS p-tau217 progressively increased with increasing disease severity, and showed good accuracy in predicting CSF biomarker positivity (area under the curve = 0.864). Similarly, we demonstrated the successful detection of glial fibrillary acidic protein and neurofilament light with strong correlations between DBS and DPS, respectively, using paired venous plasma samples. Notably, the method was also effective in individuals with Down syndrome, a population at high genetic risk for AD but in whom standard blood sampling by venipuncture may be more complicated, revealing elevated biomarkers in those with dementia compared with asymptomatic individuals. The study also explored unsupervised blood collection, finding high concordance between supervised and self-collected samples. These findings underscore the potential of dried blood collection and capillary blood as a minimally invasive, scalable approach for AD biomarker testing in research settings. Yet, further refinement of collection and analytical protocols is needed to fully translate this approach to be viable and useful as a clinical tool.
Year:
2026
Lipidomics offers potential for the early detection of Alzheimer’s disease (AD) and for elucidating the molecular mechanisms driving the progression from mild cognitive impairment (MCI) to AD. In this study, we investigated and validated the association between 139 cerebrospinal fluid (CSF) lipids and MCI-to-AD conversion. We included 400 MCI participants from the Ace Alzheimer Center Barcelona (ACE) cohort, all free of type 2 diabetes, comprising both ATN+ and ATN− individuals. After a median follow-up of 2.1 years, 142 participants progressed to AD dementia. We identified a multi-lipid signature of 11 lipids (including phosphatidylcholines, lysophosphatidylcholines, triglycerides, phosphatidylethanolamines, lysophosphatidylethanolamines and phosphatidylinositols) in CSF, which was associated with increased AD progression (HR = 1.85, 95% CI: 1.53–2.27). This signature was validated in paired plasma samples, a less invasive biofluid (HR = 1.26, 95% CI: 1.04–1.52) and in plasma samples from an external cohort of 189 participants (149 with subjective cognitive decline, 40 with MCI; β = 0.261, 95% CI: 0.022–0.500), demonstrating moderate-to-high predictive accuracy for MCI-to-AD progression. Counterfactual-based mediation analysis revealed that plasma phosphorylated tau-181 mediated up to 47% of the association between the lipid signature and AD dementia, highlighting glycerophospholipid metabolism as a key pathway. Exploratory Mendelian randomisation analyses suggested a potential causal association of lipid signature and AD, with two instrumental single-nucleotide polymorphisms mapped to loci implicated in neurodevelopmental and metabolic regulation (RBFOX1 and CDKAL1). In conclusion, our findings support the growing evidence of lipid metabolism dysregulation as an early marker of AD and identify plasma lipids reflecting CSF profiles that may be promising prognostic markers for AD dementia.
Year:
2025
Neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease, Frontotemporal dementia, and Dementia with Lewy bodies) pose diagnostic challenges due to overlapping pathology and clinical heterogeneity. We leveraged proteomic data from more than 21,000 cerebrospinal fluid and plasma samples to develop and validate explainable, boosting-based multi-disease AI classifiers. The models achieved weighted AUCs in the testing datasets of 0.97 for CSF and 0.88 for plasma, equivalent to traditional biomarkers. The model was validated with neuropathological and clinical data, confirming robust generalizability without any retraining. Using zero-shot learning, we classified disease subtypes including autosomal dominant AD and prodromal PD and clarified disease states for those with conflicting clinical information. The model also showed the ability to prioritize cognitively normal individuals at disease risk. This framework enabled the identification and quantification of continuous, individual-level disease probabilities that allow for the quantification of overlap across diseases and co-pathologies within an individual. Through this work, we establish a benchmark computational framework for enhancing diagnostic precision in NDs.
Year:
2025
Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.
Year:
2025
Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.
Year:
2025
INTRODUCTION Hippocampal sclerosis of aging (HS-aging) is frequently present in individuals over 85 who die with dementia. Recent studies suggest that some loci associated with Alzheimer’s disease (AD) may be more related to HS-aging. We aimed to find AD-associated SNPs potentially related to HS-aging. METHODS We assessed the relation of the AD polygenic risk score (AD-PRS) with hippocampal subfield volumes assessed by magnetic resonance imaging (MRI) as HS-by-proxy in 1,130 non-demented participants. We analyzed 1,708 individuals to associate their AD-PRS (83 variants) with AD alongside HS-aging. RESULTS HS-by-proxy measures of fimbria and hippocampal body and head show association with AD-PRS, SHARPIN , GRN and TNIP1 , also after replication. We replicated the stronger AD-PRS association with AD in the presence of HS-aging compared to AD alone. DISCUSSION Results show association between some AD-SNPs and HS-proxy, enriched in immune-brain axis pathways, differentiating HS-aging from AD. This insight aids in understanding their interrelationships and identifying specific therapeutic targets.
Year:
2025
High-throughput proteomic platforms are crucial to identify novel Alzheimer’s disease (AD) biomarkers and pathways. In this study, we evaluated the reproducibility and reliability of aptamer-based (SomaScan® 7k) and antibody-based (Olink® Explore 3k) proteomic platforms in cerebrospinal fluid (CSF) samples from the Ace Alzheimer Center Barcelona real-world cohort. Intra- and inter-platform reproducibility were evaluated through correlations between two independent SomaScan® assays analyzing the same samples, and between SomaScan® and Olink® results. Association analyses were performed between proteomic measures, CSF biological traits, sample demographics, and AD endophenotypes. Our 12-category metric of reproducibility combining correlation analyses identified 2428 highly reproducible SomaScan CSF measures, with over 600 proteins well reproduced on another proteomic platform. The association analyses among AD clinical phenotypes revealed that the significant associations mainly involved reproducible proteins. The validation of reproducibility in these novel proteomics platforms, measured using this scarce biomaterial, is essential for accurate analysis and proper interpretation of innovative results. This classification metric could enhance confidence in multiplexed proteomic platforms and improve the design of future panels.
Year:
2024
Background: Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) are currently underdiagnosed in the community, and early detection of cognitive deficits is crucial for timely intervention. FACEmemory®, the first completely self-administered online memory test with voice recognition, has been launched as an accessible tool to detect such deficits. This study aims to investigate the neuropsychological associations between FACEmemory subscores and cognitive composites derived from traditional paper-and-pencil neuropsychological tests and to develop an optimal algorithm using FACEmemory data and demographics to discriminate cognitively healthy (CH) individuals from those with MCI. Methods: A total of 669 participants (266 CH, 206 non-amnestic MCI [naMCI], and 197 amnestic MCI [aMCI]) were included. Multiple linear regression analyses were conducted using a cognitive composite as the dependent variable and FACEmemory subscores and demographic data (age, sex, and schooling) as independent variables. Machine learning models were compared to identify an optimal algorithm for distinguishing between CH and MCI (whole MCI, aMCI, and naMCI). Results: Multiple regression analyses showed associations between FACEmemory scores and the domains of memory (ρ = 0.67), executive functions (ρ = 0.63), visuospatial/visuoperceptual abilities (ρ = 0.55), language (ρ = 0.43), praxis (ρ = 0.52), and attention (ρ = 0.31). An optimal algorithm distinguished between CH and aMCI, achieving a FACEmemory cutoff score of 44.5, with sensitivity and specificity values of 0.81 and 0.72, respectively. Conclusions: FACEmemory is a promising online tool for identifying early cognitive impairment, particularly aMCI. It may contribute to addressing the underdiagnosis of MCI and dementia in the community and in promoting preventive strategies.
Year:
2024
TREM2 encodes a microglial membrane receptor involved in the disease-associated microglia (DAM) phenotype whose activation requires the transmembrane interaction with TYROBP. Mutations in TREM2 represent a high-impact risk factor for Alzheimer’s disease (AD) which turned TREM2 into a significant drug target. We present a bacterial two-hybrid (B2H) system designed for high-throughput screening of modulators for the TREM2-TYROBP transmembrane interaction. In a pilot study, 315 FDA-approved drugs were analyzed to identify potential binding modifiers. Our pipeline includes multiple filtering steps to ensure candidate specificity. The screening suggested two potential candidates that were finally assayed in the human microglial cell line HMC3. Upon stimulation with anti-TREM2 mAb, pSYK/SYK ratios were calculated in the presence of the candidates. As a result, we found that varenicline, a smoking cessation medication, can be considered as a transmembrane agonist of the TREM2-TYROBP interaction.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (109)
Stefanie Heilmann-Heimbach
Head of Laboratory, Research Group Leader
University Hospital Bonn
Ruth Frikke-Schmidt
Professor, Chief Physician, MD PhD DMSc
-
Luis M Real
Profesor
Universidad de Sevilla
Maria Jesús Bullido Gómez-Heras
Researcher
Universidad Autónoma de Madrid
Elena Sánchez-López
Assitant Professor
University of Barcelona
Pau Pastor
Institut Català de la Salut
Daniele Altomare
Scuola universitaria professionale della Svizzera italiana
Eloy Rodriguez-Rodríguez
Instituto de Investigación Marqués de Valdecilla
innocenzo rainero
University of Turin
Alex Rovira
Head of Neuroradiology
Hospital Universitari Vall d'Hebron
Henrik Zetterberg
Professor
University of Gothenburg
Yun Ju Sung
Washington University in St. Louis
Harro Seelaar
Neurologist
Erasmus MC
Philippe Amouyel
Full Professor
Centre Hospitalier Régional Universitaire de Lille
Jesper Qvist Thomassen
Senior Scientist
Rigshospitalet
Tony Wyss-Coray
Professor
Stanford University
Johannes Kornhuber
-
Amanda Cano
Head of Molecular Biology & Biomarkers program
-
Henne Holstege
Professor
KU Leuven
Marco Spallazzi
Adjunt professor
University of Parma
Markus Nöthen
Professor, Director
University Hospital Bonn
Benedetta Nacmias
University of Florence
Laura Ibanez
Assistant Professor
Washington University in Saint Louis School of Medicine
Nicholas Seyfried
Professor
Emory University
Suzanne Schindler
Associate Professor
Washington University in St. Louis
Lucilla Parnetti
Professor of Neurology
University of Perugia
Caroline Jonson
University of California, San Francisco
Vilmundur Gudnason
Professor
University of Iceland
Pieter Jelle Visser
Karolinska Institutet
Jordi Pérez-Tur
Coordinador Adjunto al Área Global Vida
Agencia Estatal Consejo Superior de Investigaciones Científicas
Antoni Camins
University of Barcelona
Patrizia Mecocci
Director
Karolinska Institutet
Caroline Graff
Professor,MD PhD
Karolinska Institutet
Henna Martiskainen
University of Eastern Finland
Amy Kit Yu Fu
Research Professor
The Hong Kong University of Science and Technology
Arvid Rongve
Professor
University of Bergen
Jean-Charles Lambert
Head of research unit
INSERM
Bryan Strange
Profesor I3
Universidad Politécnica de Madrid
Betty Tijms
Senior researcher
VU medisch centrum
Simon Laws
Professor
Edith Cowan University
María del Carmen Mañas Padilla
Coordinadora Adjunta Máster en Nueropsicología y Educación
Universidad Internacional de La Rioja
Nancy Yuk-Yu Ip
The Morningside Professor of Life Science
The Hong Kong University of Science and Technology
Katja Scheffler
Associate Professor
Norwegian University of Science and Technology
John Morris
Professor
Washington University School of Medicine
Takeshi Ikeuchi
Professor
Brain Research Institute, Niigata University
Jonathan Vogelgsang
Harvard University
Erik Johnson
Assistant Professor
Emory University School of Medicine
Meghan Campbell
Washington University in Saint Louis School of Medicine
Ciyang Wang
Washington University in St. Louis
Geir Selbaek
Professor
University of Oslo
Nil Novau-Ferré
Part-time professor
Universidad Rovira i Virgili
Timothy Hohman
Professor
Vanderbilt University Medical Center
Pablo Mir
-
Norbert Scherbaum
Professor for Clinical Addiction Research
University of Duisburg-Essen Faculty of Medizin
Tormod Fladby
Professor ll of Neurology
University of Oslo
Margda Waern
University of Gothenburg
Muhammad Ali
Assistant Professor
Washington University in St. Louis
Silke Kern
Professor/ Chief Physician
University of Gothenburg
Miren Ettcheto
Profesor agregado
University of Barcelona
Andrew Saykin
Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
Eric Dammer
Scientist, Bioinformatics
Emory University
Srdjan Djurovic
Professor at University of Oslo
University of Oslo
Sami Heikkinen
Research Director
University of Eastern Finland
Najaf Amin
Associate Professor
University of Oxford
Wiesje van der Flier
Scientific director
VU medisch centrum
Peter Holmans
Professor of Biostatistics and Genetic Epidemiology
Cardiff University
Ted Wilson
Provost's Assistant Professor of Neuroimmunology & Brain Science
Brown University
David M. Holtzman
Washington University School of Medicine
Thor Aspelund
Professor
University of Iceland
Dan Rujescu
Head of Clinical Division of General Psychiatry
Medical University of Vienna
Alessio Squassina
Dalhousie University
Carole Dufouil
Director of research
INSERM
Virginia M-Y Lee
Professor
University of Pennsylvania
Robert Perneczky
Professor
Ludwig-Maximilians-Universität München
Martin Ingelsson
Specialist
Uppsala University Hospital
Hilkka Soininen
Kuopio University Hospital
Gael Nicolas
PUPH
University of Rouen
Riccardo E Marioni
University of Edinburgh
Anssi Lipponen
University of Eastern Finland
Mònica Bulló
Professor
Universitat Rovira i Virgili
Patrick Kehoe
Academic , Gestetner Professor of Translational Dementia Research
University of Bristol
Silvana Sarria Estrada
Hospital Universitari Vall d'Hebron
Alison Goate
Professor and Chair
Icahn School of Medicine at Mount Sinai
Alfredo Ramirez
University of Texas Health Science Center at San Antonio
INGVILD SALTVEDT
Professor
Norwegian University of Science and Technology
Dag Aarsland
Professor and Head of Department
King’s College London
Daniela Galimberti
Associate Professor
Università degli Studi di Torino
Carlos Cruchaga
Professor
Washington University in St. Louis
Paul T. Kotzbauer
-
Ainhoa García-Sánchez
Profesora de Técnicas de Aprendizaje Automático - Directora de Trabajos de Fin de Máster
Universidad Internacional de La Rioja
Ole A. Andreassen
Oslo University Hospital
Allan I. Levey
Emory University School of Medicine
Lucio Tremolizzo
Associate Professor of Neurology
University of Milano-Bicocca
Valentina Escott-Price
Professor
Cardiff University
Ville Leinonen
Professor
University of Eastern Finland
Lutz Froelich
Head
Zentralinstitut für Seelische Gesundheit
Rebecca Sims
Senior Research Fellow
Cardiff University
Barbara Borroni
Docenti di ruolo di IIa fascia
University of Brescia
Lars Bertram
Professor of Genome Analytics
University of Lübeck
Jose Luis Royo
University of Malaga
Valborg Gudmundsdottir
Research Assistant Professor
University of Iceland
Mikko Hiltunen
University of Eastern Finland
Cornelia Van Duijn
Professor
University of Oxford
Alberto Lleó
Director
Hospital de la Santa Creu i Sant Pau
Erik Stomrud
Lund University
Adriana Castro-Zavala
Instituto de Investigación Biomédica de Málaga
Sterling Johnson
Professor
University of Wisconsin-Madison
Menghan Liu
Washington University in St. Louis
Farhad Imam
Assistant Professor
University of California, San Diego
Make your next move.
Prepare your application
Review drafts before you send them.